Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 94.56
ARWR's Cash to Debt is ranked higher than
52% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. ARWR: 94.56 )
Ranked among companies with meaningful Cash to Debt only.
ARWR' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 54.35 Max: No Debt
Current: 94.56
Equity to Asset 0.79
ARWR's Equity to Asset is ranked higher than
63% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARWR: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
ARWR' s Equity to Asset Range Over the Past 10 Years
Min: -39.56  Med: 0.76 Max: 0.95
Current: 0.79
-39.56
0.95
Interest Coverage N/A
ARWR's Interest Coverage is ranked higher than
52% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARWR: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARWR' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.00 Max: 9999.99
Current: N/A
N/A
9999.99
F-Score: 3
Z-Score: 2.67
M-Score: -3.99
WACC vs ROIC
20.12%
-434.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -31964.84
ARWR's Operating margin (%) is ranked lower than
96% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. ARWR: -31964.84 )
Ranked among companies with meaningful Operating margin (%) only.
ARWR' s Operating margin (%) Range Over the Past 10 Years
Min: -30443.43  Med: -3445.44 Max: -522.9
Current: -31964.84
-30443.43
-522.9
Net-margin (%) -31546.48
ARWR's Net-margin (%) is ranked lower than
96% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. ARWR: -31546.48 )
Ranked among companies with meaningful Net-margin (%) only.
ARWR' s Net-margin (%) Range Over the Past 10 Years
Min: -33502.86  Med: -2835.25 Max: -511.74
Current: -31546.48
-33502.86
-511.74
ROE (%) -72.94
ARWR's ROE (%) is ranked lower than
73% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. ARWR: -72.94 )
Ranked among companies with meaningful ROE (%) only.
ARWR' s ROE (%) Range Over the Past 10 Years
Min: -225.02  Med: -94.07 Max: -28.66
Current: -72.94
-225.02
-28.66
ROA (%) -62.52
ARWR's ROA (%) is ranked lower than
77% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. ARWR: -62.52 )
Ranked among companies with meaningful ROA (%) only.
ARWR' s ROA (%) Range Over the Past 10 Years
Min: -154.73  Med: -76.38 Max: -22.16
Current: -62.52
-154.73
-22.16
ROC (Joel Greenblatt) (%) -1875.89
ARWR's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ARWR: -1875.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARWR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11843.37  Med: -2255.93 Max: -584.83
Current: -1875.89
-11843.37
-584.83
Revenue Growth (3Y)(%) -18.60
ARWR's Revenue Growth (3Y)(%) is ranked lower than
71% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ARWR: -18.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARWR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -49.15 Max: 65
Current: -18.6
0
65
EBITDA Growth (3Y)(%) -2.10
ARWR's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ARWR: -2.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARWR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53  Med: -17.90 Max: 245.2
Current: -2.1
-53
245.2
EPS Growth (3Y)(%) -5.50
ARWR's EPS Growth (3Y)(%) is ranked lower than
51% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. ARWR: -5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARWR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.8  Med: -15.30 Max: 54.1
Current: -5.5
-55.8
54.1
» ARWR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ARWR Guru Trades in Q2 2015

Steven Cohen 22,200 sh (New)
» More
Q3 2015

ARWR Guru Trades in Q3 2015

Paul Tudor Jones 17,447 sh (New)
Steven Cohen Sold Out
» More
Q4 2015

ARWR Guru Trades in Q4 2015

Paul Tudor Jones 41,313 sh (+136.79%)
» More
Q1 2016

ARWR Guru Trades in Q1 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SVA, NAS:CGEN, OTCPK:SPHDF, NAS:TRVN, NAS:VSAR, OTCPK:VNLPY, NAS:AKBA, NAS:ASND, OTCPK:MEOBF, NAS:NLNK, NAS:TGTX, OTCPK:ELVAF, NAS:ARDX, NAS:VTAE, NAS:OMED, NAS:VYGR, NAS:BLCM, NAS:NERV, NAS:NDRM, NAS:CTMX » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.

Arrowhead Pharmaceuticals Inc, formerly Arrowhead Research Corp was originally incorporated in South Dakota in the year 1989, and was reincorporated in Delaware in 2000. The Company is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. Its products include ARC-520, Adipotide. The Company controls 306 patents. The Company and its products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the FDCA), and other laws within the Public Health Service Act.

Ratios

vs
industry
vs
history
P/B 4.55
ARWR's P/B is ranked lower than
63% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. ARWR: 4.55 )
Ranked among companies with meaningful P/B only.
ARWR' s P/B Range Over the Past 10 Years
Min: 1.65  Med: 4.71 Max: 71.58
Current: 4.55
1.65
71.58
P/S 1130.00
ARWR's P/S is ranked lower than
96% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. ARWR: 1130.00 )
Ranked among companies with meaningful P/S only.
ARWR' s P/S Range Over the Past 10 Years
Min: 4.04  Med: 164.16 Max: 4132.5
Current: 1130
4.04
4132.5
Current Ratio 4.71
ARWR's Current Ratio is ranked higher than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ARWR: 4.71 )
Ranked among companies with meaningful Current Ratio only.
ARWR' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.38 Max: 302.61
Current: 4.71
0.01
302.61
Quick Ratio 4.71
ARWR's Quick Ratio is ranked higher than
53% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. ARWR: 4.71 )
Ranked among companies with meaningful Quick Ratio only.
ARWR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 5.42 Max: 302.61
Current: 4.71
0.01
302.61

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.19
ARWR's Price/Net Cash is ranked lower than
64% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. ARWR: 8.19 )
Ranked among companies with meaningful Price/Net Cash only.
ARWR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.05  Med: 7.05 Max: 103.64
Current: 8.19
0.05
103.64
Price/Net Current Asset Value 7.34
ARWR's Price/Net Current Asset Value is ranked lower than
64% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. ARWR: 7.34 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARWR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.04  Med: 7.00 Max: 70.89
Current: 7.34
0.04
70.89
Price/Tangible Book 6.73
ARWR's Price/Tangible Book is ranked lower than
68% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ARWR: 6.73 )
Ranked among companies with meaningful Price/Tangible Book only.
ARWR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.04  Med: 6.53 Max: 54.5
Current: 6.73
0.04
54.5
Price/Median PS Value 6.89
ARWR's Price/Median PS Value is ranked lower than
95% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ARWR: 6.89 )
Ranked among companies with meaningful Price/Median PS Value only.
ARWR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.59 Max: 22.38
Current: 6.89
0.03
22.38
Earnings Yield (Greenblatt) (%) -29.50
ARWR's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. ARWR: -29.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARWR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -105.61  Med: 0.00 Max: 0
Current: -29.5
-105.61
0

More Statistics

Revenue (TTM) (Mil) $0.26
EPS (TTM) $ -1.36
Beta2.48
Short Percentage of Float16.80%
52-Week Range $3.07 - 9.36
Shares Outstanding (Mil)59.96

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Sep16 Sep17
Revenue (Mil $) 0 0
EPS ($) -1.43 -1.38
EPS w/o NRI ($) -1.43 -1.38
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US :... Jul 22 2016
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARWR-US :... Jul 11 2016
Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Jul 06 2016
Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 06 2016
ETF’s with exposure to Arrowhead Pharmaceuticals, Inc. : July 1, 2016 Jul 01 2016
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US :... Jun 27 2016
Arrowhead Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARWR) : June 17, 2016 Jun 17 2016
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US :... Jun 15 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B... Jun 09 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B... Jun 09 2016
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B... Jun 09 2016
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference Jun 03 2016
Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference Jun 03 2016
ARWR: Update on Financials for Fiscal Second Quarter Ended March 31, 2016 May 20 2016
ARROWHEAD PHARMACEUTICALS, INC. Financials May 19 2016
Coverage initiated on Arrowhead by Chardan Capital Markets May 19 2016
ETF’s with exposure to Arrowhead Pharmaceuticals, Inc. : May 18, 2016 May 17 2016
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q2, 2016 By the Numbers May 17 2016
Arrowhead Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARWR-US :... May 16 2016
Edited Transcript of ARWR earnings conference call or presentation 10-May-16 8:30pm GMT May 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)